SRZN

Surrozen, Inc. (SRZN) - Q3 2025 10-Q Summary

Business Context and Reporting Period

Surrozen, Inc. is a biotechnology company focused on discovering and developing drug candidates to selectively modulate the Wnt pathway, with a current emphasis on ophthalmology. This report covers the quarterly period ended September 30, 2025. The company is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Collaboration and license revenue dropped to zero in Q3 2025 compared to $10.0 million in Q3 2024, as the prior year included a milestone payment from Boehringer Ingelheim. Current revenue is driven by related-party research services ($0.98 million).
• Significant Net Loss: The Q3 2025 net loss of $71.6 million was driven primarily by a $40.7 million loss on the change in fair value of tranche liability and a $20.9 million net other expense (largely due to warrant liability fair value changes).
• Capital Raise Impact: In March 2025, the company executed a two-tranche private placement (2025 PIPE). The first tranche closed with net proceeds of approximately $71.2 million. The accounting treatment of the tranche liability resulted in a $71.1 million non-cash loss on execution recorded in the first half of the year.
• Liquidity Improvement: Cash and cash equivalents increased from $34.6 million at year-end 2024 to $81.3 million at Q3 2025, primarily due to the 2025 PIPE financing.

Guidance, Outlook, and Risks

• Product Pipeline: The company is advancing SZN-8141 and SZN-8143 for retinal diseases and SZN-113 for Fuchs' Endothelial Corneal Dystrophy. Development of SZN-043 was discontinued in Q1 2025 due to insufficient clinical benefit signals.
• Financing Milestone: A second tranche of the 2025 PIPE, expected to raise approximately $98.6 million, is contingent upon the FDA clearance of the Investigational New Drug (IND) application for SZN-8141 by October 31, 2026.
• Liquidity Outlook: Management believes current cash resources are sufficient to fund operations for at least the next 12 months. However, additional capital will be required to advance clinical trials and commercialization.
• Recent Termination: In October 2025, the company received notice that its research collaboration with TCGFB, Inc. was terminated effective November 13, 2025. No termination penalties were incurred.
• Risk Factors: Key risks include the high cost of clinical development, the uncertainty of regulatory approval, the potential for further dilution from warrant exercises or future financing, and the impact of fair value changes on warrant and tranche liabilities on reported earnings.

Investor Verification Checklist

• Tranche Liability Valuation: Verify the assumptions used to value the remaining second tranche liability ($51.65 million) and the potential for future non-cash losses or gains impacting net income.
• Warrant Liability Exposure: Assess the sensitivity of the $53.54 million warrant liability to changes in the company's stock price and volatility, as these fluctuations directly impact the bottom line.
• IND Filing Timeline: Confirm the progress toward the IND filing for SZN-8141, as this is the trigger for the $98.6 million second tranche funding.
• Related Party Revenue: Note that current revenue is derived from a related-party agreement (TCGFB) that has been terminated; verify the sustainability of future revenue streams.
• Dilution Potential: Review the total number of shares issuable upon exercise of outstanding warrants (approx. 12.9 million) and options (1.24 million) relative to the 8.57 million shares currently outstanding.